AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8552463 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing on a da Vinci window (vertical glass pane)
Number of subjects: 0
Study 8552463 — intervention group
Group type: COMPARATOR
Intervention: Drawing on paper (flat on the table)
Number of subjects: 0
Study 8552463 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoid model
Number of subjects: 0
Study 8552463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilted rectangle model
Number of subjects: 0
Study 2216204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 gel intracervically (N = 52)
Number of subjects: 100
Study 2216204 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 gel intravaginally (N = 48)
Number of subjects: 100
Study 350861 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol (administered once weekly)
Number of subjects: 25
Study 350861 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine (administered daily)
Number of subjects: 25
Study 30905729 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-in-stent (SIS)
Number of subjects: 69
Study 30905729 — intervention group
Group type: COMPARATOR
Intervention: Stent-by-stent (SBS)
Number of subjects: 69
Study 28235027 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E gp120 alone
Number of subjects: 0
Study 28235027 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV alone
Number of subjects: 0
Study 28235027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ALVAC-HIV and AIDSVAX B/E gp120
Number of subjects: 0
Study 28235027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25468399 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided deep breathing group (GDBG)
Number of subjects: 150
Study 25468399 — intervention group
Group type: COMPARATOR
Intervention: All groups (including GDBG, MLG, SSG)
Number of subjects: 150
Study 24131602 — intervention group
Group type: EXPERIMENTAL
Intervention: Widex SoundTracker
Number of subjects: 20
Study 24131602 — intervention group
Group type: COMPARATOR
Intervention: Real-ear analyzers (Verifit and 6500)
Number of subjects: 20
Study 21829664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 669
Study 21829664 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 669
Study 19561524 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program (1 year duration, including respiratory reeducation training and muscular training)
Number of subjects: 50
Study 19561524 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Number of subjects: 50
Study 19561524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 17413093 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk diet (37.5 g/d)
Number of subjects: 28
Study 17413093 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 28
Study 17413093 — intervention group
Group type: EXPERIMENTAL
Intervention: Soyflour diet
Number of subjects: 28
Study 17413093 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole soybean diet
Number of subjects: 28
Study 15197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin (2 microg)
Number of subjects: 15
Study 15197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desmopressin (0.2 mg)
Number of subjects: 15
Study 15197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime intravenous desmopressin (2 microg)
Number of subjects: 15
Study 15197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime oral desmopressin (0.2 mg)
Number of subjects: 15
Study 11317951 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Sensory Stimulation (MSS)
Number of subjects: 50
Study 11317951 — intervention group
Group type: COMPARATOR
Intervention: Activity sessions (Control)
Number of subjects: 50
Study 9569997 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg under fasting conditions
Number of subjects: 24
Study 9569997 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg after a high-fat breakfast
Number of subjects: 24
Study 7914751 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study 7914751 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 0
Study 7914751 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 7914751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SASP)
Number of subjects: 0
Study 3073524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily for up to 12 weeks)
Number of subjects: 138
Study 3073524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g four times daily for up to 12 weeks)
Number of subjects: 138
Study 31689329 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School Start II (HSS II) intervention
Number of subjects: 24
Study 28245243 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin intravenous infusion (80 μg/kg/d for 60 min, then 30 μg/kg/d for 60 min)
Number of subjects: 40
Study 28245243 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin (single 2-mg i.v. bolus)
Number of subjects: 40
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime feeding of casein (CAS)
Number of subjects: 37
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime feeding of whey (WH)
Number of subjects: 37
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime feeding of carbohydrate (CHO)
Number of subjects: 37
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (2 days of resistance training and 1 day of high-intensity interval training)
Number of subjects: 37
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime feeding of CAS combined with exercise training
Number of subjects: 37
Study 25409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime feeding for 4 weeks combined with exercise training
Number of subjects: 37
Study 23509083 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous platelet gel (PG)
Number of subjects: 21
Study 21462008 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading intervention
Number of subjects: 14
Study 21462008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 19796051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, or 100 mg)
Number of subjects: 841
Study 19796051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 16881776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 107
Study 16881776 — intervention group
Group type: COMPARATOR
Intervention: Exposure group therapy
Number of subjects: 107
Study 16881776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 107
Study 16881776 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy
Number of subjects: 107
Study 15058150 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins for primary prevention (patients with hypercholesterolemia but no known CHD)
Number of subjects: 0
Study 15058150 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins for secondary prevention (patients with known CHD)
Number of subjects: 0
Study 11353547 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency flow interruption ventilation (HFFI)
Number of subjects: 36
Study 9602198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide 1 mg every 12 hours for 5 days, then 500 micrograms every 12 hours for a total of 6 weeks
Number of subjects: 40
Study 9602198 — intervention group
Group type: COMPARATOR
Intervention: Nebulized placebo (0.9% saline) for 6 weeks
Number of subjects: 40
Study 7973480 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser (GA-AL-AS 30 mW/830 nm low power laser)
Number of subjects: 36
Study 7973480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2537699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 5 mg benazepril hydrochloride
Number of subjects: 26
Study 4909817 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium capsules (50 mg, four times a day for 12 weeks)
Number of subjects: 100
Study 4909817 — intervention group
Group type: COMPARATOR
Intervention: Control group (capsule identical in every respect except that it did not contain carbenoxolone)
Number of subjects: 100
Study 31984682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at 10 Hz in ANTHEM-HF
Number of subjects: 0
Study 31984682 — intervention group
Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) in NECTAR-HF
Number of subjects: 0
Study 31984682 — intervention group
Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) in INOVATE-HF
Number of subjects: 0
Study 30821139 — intervention group
Group type: EXPERIMENTAL
Intervention: AF1q gene polymorphism detection using PCR-RFLP
Number of subjects: 40
Study 30821139 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic analysis using iTraq
Number of subjects: 40
Study 28110812 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 group (n = 25)
Number of subjects: 49
Study 28110812 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 24)
Number of subjects: 49
Study 26052147 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g Beta-Alanine (BA) + 34 g dextrose
Number of subjects: 12
Study 26052147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (34 g dextrose)
Number of subjects: 12
Study 23719347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infant cotrimoxazole
Number of subjects: 2369
Study 23719347 — intervention group
Group type: COMPARATOR
Intervention: No extended antiretroviral prophylaxis
Number of subjects: 2369
Study 23719347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (2000-2499 g)
Number of subjects: 2369
Study 23719347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 2369
Study 23719347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low infant WBC count at birth
Number of subjects: 2369
Study 21709060 — intervention group
Group type: EXPERIMENTAL
Intervention: m-SVG
Number of subjects: 3014
Study 21709060 — intervention group
Group type: COMPARATOR
Intervention: s-SVG
Number of subjects: 3014
Study 19536128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg once daily)
Number of subjects: 342
Study 19536128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 17074270 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual ventilation (IV) group
Number of subjects: 30
Study 17074270 — intervention group
Group type: COMPARATOR
Intervention: Lower‐tidal‐volume (LTV) group
Number of subjects: 30
Study 16295054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsating electrostatic field (PESF) therapy, 30 min daily exposure, adjusted between 2 and 9 kV
Number of subjects: 14
Study 15332347 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day upon awakening
Number of subjects: 91
Study 15332347 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day at bedtime
Number of subjects: 91
Study 15332347 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day at bedtime (polytherapy)
Number of subjects: 91
Study 10742313 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control intervention (training of child care staff about transmission of infection, handwashing, and aseptic nosewiping technique)
Number of subjects: 311
Study 10742313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 311
Study 8932265 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor livers with up to 30% fatty infiltration
Number of subjects: 59
Study 1402213 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (INB) 400 mg daily
Number of subjects: 113
Study 1402213 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 900 mg daily plus dipyridamole (DP) 225 mg daily
Number of subjects: 113
Study 3919790 — intervention group
Group type: COMPARATOR
Intervention: 26% oxygen breathing
Number of subjects: 14
Study 2975582 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 75 micrograms gestodene
Number of subjects: 11
Study 2975582 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 150 micrograms desogestrel
Number of subjects: 11
Study 2975582 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 11
Study 29286989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based stress management program for 10 weeks
Number of subjects: 0
Study 29286989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28790966 — intervention group
Group type: EXPERIMENTAL
Intervention: Online synchronous Internet streaming classroom using the Adobe Connect e‐learning platform
Number of subjects: 274
Study 28790966 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom
Number of subjects: 274
Study 26137881 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 670
Study 26137881 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) in rash subgroup
Number of subjects: 670
Study 26137881 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (placebo)
Number of subjects: 670
Study 23811987 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablet (ODT)
Number of subjects: 20
Study 23811987 — intervention group
Group type: COMPARATOR
Intervention: Intranasal desmopressin
Number of subjects: 20
Study 23811987 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT
Number of subjects: 20
Study 23811987 — intervention group
Group type: COMPARATOR
Intervention: Intranasal desmopressin to desmopressin ODT
Number of subjects: 20
Study 21692282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus herbal medicine
Number of subjects: 160
Study 21692282 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine
Number of subjects: 160
Study 21692282 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160
Study 21692282 — intervention group
Group type: COMPARATOR
Intervention: Glycerine Enema
Number of subjects: 160
Study 19930678 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free legislation in Wales implemented in April 2007
Number of subjects: 1750
Study 19930678 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free legislation in Wales
Number of subjects: 1750
Study 17074342 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic assessment of the luteal phase endometrium using Noyes criteria and immunohistochemical analysis for expression of inhibin, activin, and follistatin subunits
Number of subjects: 43
Study 17074342 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler analysis for perifollicular and endometrial blood flow
Number of subjects: 43
Study 17074342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of E(2), LH, FSH, P, and inhibin B at the time of LH surge and at LH +7 days
Number of subjects: 43
Study 15193852 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Start Program) with > or =75% of visits called for in the model
Number of subjects: 643
Study 15193852 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Start Program)
Number of subjects: 643
Study 11681532 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 57
Study 11681532 — intervention group
Group type: COMPARATOR
Intervention: Sequential methotrexate and 5-fluorouracil
Number of subjects: 57
Study 11681532 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15-3
Number of subjects: 57
Study 11681532 — intervention group
Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 57
Study 11681532 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA and TPS
Number of subjects: 57
Study 9779028 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg every 12 h subcutaneously
Number of subjects: 3171
Study 9779028 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) as a continuous intravenous infusion
Number of subjects: 3171
Study 7830861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltered dialysate
Number of subjects: 11
Study 7830861 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate dialysate
Number of subjects: 11
Study 3418366 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Day Hospital (ADH)
Number of subjects: 442
Study 3418366 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 442
Study 30391995 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli; 0.8 ng/kg of body weight)
Number of subjects: 115
Study 30391995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 115
Study 27385478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 73
Study 27385478 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 73
Study 25359424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral T3 treatment (20 μg per day for 3 months)
Number of subjects: 13
Study 25359424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22819624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg clonazepam
Number of subjects: 0
Study 22819624 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 0
Study 22819624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg clonazepam
Number of subjects: 0
Study 22819624 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term memory testing 4 h after reactivation
Number of subjects: 0
Study 21992076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.45%
Number of subjects: 122
Study 21992076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 122
Study 21992076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 122
Study 21992076 — intervention group
Group type: EXPERIMENTAL
Intervention: Amfenac (active metabolite of nepafenac)
Number of subjects: 122
Study 19130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0
Study 19130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 19130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy adults
Number of subjects: 0
Study 19130899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic Parkinson's disease
Number of subjects: 0
Study 19130899 — intervention group
Group type: COMPARATOR
Intervention: Control (subjective vs objective cognition)
Number of subjects: 0
Study 19130899 — intervention group
Group type: COMPARATOR
Intervention: Control (mood vs objective cognitive performance)
Number of subjects: 0
Study 17547048 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-1: albendazole 800 mg/day twice daily for 3 consecutive days
Number of subjects: 115
Study 17547048 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-2: albendazole 800 mg/day twice daily for 5 consecutive days
Number of subjects: 115
Study 17547048 — intervention group
Group type: COMPARATOR
Intervention: Regimen-1
Number of subjects: 115
Study 17547048 — intervention group
Group type: COMPARATOR
Intervention: Regimen-2
Number of subjects: 115
Study 15385655 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14527
Study 15385655 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14527
Study 15385655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both captopril and valsartan
Number of subjects: 14527
Study 15385655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14527
Study 11687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycogen trial
Number of subjects: 6
Study 11687509 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 6
Study 9405962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg t.i.d)
Number of subjects: 342
Study 9405962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 8199696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 41
Study 8199696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (600 mg/day)
Number of subjects: 41
Study 8199696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day) and Ursodeoxycholic acid (600 mg/day)
Number of subjects: 41
Study 8199696 — intervention group
Group type: COMPARATOR
Intervention: Control (neither drug)
Number of subjects: 41
Study 3649524 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning sessions to promote autonomy (6 sessions, 1 hour each)
Number of subjects: 92
Study 31173870 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogliptin 2.5-600 mg
Number of subjects: 104
Study 31173870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 31173870 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogliptin 25-400 mg
Number of subjects: 104
Study 31173870 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogliptin 400 mg
Number of subjects: 104
Study 28401843 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting Intervention (COS-P)
Number of subjects: 141
Study 28401843 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 141
Study 25779953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigatuzumab (TIG) with nab-paclitaxel (nab-PAC)
Number of subjects: 64
Study 25779953 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel (nab-PAC)
Number of subjects: 64
Study 22552615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal technique (TP)
Number of subjects: 80
Study 22552615 — intervention group
Group type: COMPARATOR
Intervention: Outside-in technique (OI)
Number of subjects: 80